Subsidiary of Jiangsu Hengrui Pharmaceuticals (600276.SH) Receives Approval Notice for Clinical Trial of Injectable HRS-4029

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiaries Fujian Shengdi Pharmaceutical Co., Ltd. and Beijing Shengdi Pharmaceutical Co., Ltd. have recently received the approval and issuance of the "Drug Clinical Trial Approval Notice" for injectable HRS-4029 from the National Medical Products Administration (NMPA). They will soon begin clinical trials. In accordance with the "Drug Administration Law of the People's Republic of China" and related regulations, after review, the clinical trial application for injectable HRS-4029 received on December 12, 2024 meets the relevant requirements for drug registration. The product has been approved to conduct clinical trials for "acute ischemic stroke".